Award Statement
I. Fellowship Award
A. Please call the Damon Runyon Cancer Research Foundation at 212.455.0520 or email
alexi.studebaker@damonrunyon.org as soon as possible to accept or decline the award and to confirm the startdate.
B. The sponsoring investigator, institutional representative and fellowship recipient must sign the attachedaward acceptance form, include the Awardee’s ORCID iD (https://orcid.org/register) and return it to theFoundation within ten (10) working days following notification.
C. The fellowship recipient must email (alexi.studebaker@damonrunyon.org)• A brief paragraph describing in layman's terms how the project is relevant to cancer and to which
specific types of cancer the work relates.
• Two digital color photographs (at least 3 square inches, jpg at 300 dpi) of the recipient in a laboratory
setting, which may be used for fundraising purposes to publicize the Foundation's outstanding
postdoctoral cancer research program.
• A personal statement, to include:o a biography (where awardee was born and raised, any relevant family history, where theyattended college, etc.)
o personal motivations for pursuing cancer researcho other awards received, both scientific and non-scientifico outside interests (e.g. sports, clubs, hobbies) and community involvement• Completed Expense Allowance Usage Form
• If the awardee would like to have a media release announcing the award sent to a local and/or
hometown newspaper, please include the name, address, fax number and email address of thenewspaper.
D. The award may not be used for institutional overhead or indirect costs.
E. In addition to the fellowship stipend, a sum of $2,000 is awarded each year to the laboratory in which theFellow is working and can be used by the Fellow for his/her educational and scientific expenses. With awritten request to the Foundation from the Fellow, the expense allowance may be used to defray the costof health benefits. The Fellow determines how he/she would like to spend the money with approval from
his/her sponsor. It is not an allowance for institutional overhead, postdoctoral scholar registration fees or
postdoctoral fellowship taxes. Institutions may not automatically deduct any fees from this allowance
without the Fellow’s approval. Any unexpended expense allowance may be carried over to the next award
year, but any unexpended stipend must be returned to the Foundation at the end of each fellowship year. If
you have any questions on how the money may be spent, please contact the Foundation.
F. The Foundation also provides a Dependent Child Allowance of $1,000 per child per year. (There is noallowance for a spouse.) Eligible Fellows must provide a copy of the birth or adoption certificate for each child.
Payment of this allowance will be included in the first payment to the host institution and annually thereafter on
the anniversary of the Fellowship's activation date.
1

G. Supplementation of stipends is permitted from either the host institution or sponsor’s grants, but not by anyother fellowship award or grant.
Fellows are permitted to obtain additional awards or grants to cover research expenses only. Fellows are notpermitted to hold any other award or grant that supplements their stipend. Fellows are required to seek approval
from the Foundation before applying for any other award or grant. Budgetary overlap is not allowed.
Therefore, it is critical that all current and pending grant support for your research be reported to the Foundationand the relationship of that support to the Damon Runyon funded project be explained.
Activation of a fellowship award is as follows:
Application Due by:August 15
March 15

FAC Meeting:
NovemberMay

Award Begins the First Day of:_____
January, February, March or April
July, August, September or October

The Damon Runyon Cancer Research Foundation will consider requests to revise the activation date of afellowship within the timetable above. Contact the Foundation well in advance of the proposed start date toreceive approval. All awards are activated on the first of the month.
II. ReportingA.
Scientific Progress Reports: Second-, third- and fourth-year funding of awards is contingent uponsatisfactory review of the annual progress reports. All reports are kept strictly confidential. The reports serveas an auditing tool to monitor research progress and assure that the Fellow’s research is on target with thefunded project.
At the end of the 11th, 23rd and 35th months of funding, the Fellow must submit a detailed progress report that
includes:1. A summary of research performed during the award year and evaluation of the results. The summary
should be technical, but targeted to a general scientific audience. It should be sufficiently detailed suchthat the Fellow’s research activities over the award year are clearly articulated. Figures and references
may be included if appropriate. The report must be signed by both the Fellow and the Sponsor. The
report should not exceed three pages.
2. A brief, lay abstract of research performed during the award year, including how the research isrelevant to cancer. The lay summary should not exceed one page.
3. A bibliography of publications from the award year (submit pdf copies of publications).
4. A request for Open Access fee reimbursement, if applicable. (see VI-C)
5. A list of conferences and seminars attended and presentations given during the award year.
6. A brief description of collaborations and partnerships related to the Damon Runyon-funded research,with either academic and/or industry scientists. Please identify your collaborator(s) and his/heracademic/industrial affiliation(s).
7. A brief summary, from the Sponsor, assessing the Fellow’s scientific progress and professional
development.
8. A completed intellectual property disclosure form.
9. A completed expense allowance usage form.
At the completion of the fellowship, the Fellow must submit a detailed progress report that includes:
1. A summary of research performed during the period of the Fellowship and evaluation of the results.
The summary should be technical, but targeted to a general scientific audience. It should be sufficiently
detailed such that the Fellow’s research activities over the award period are clearly articulated. Figures2and references may be included if appropriate. The report must be signed by both the Fellow and theSponsor. The report should not exceed three pages.
2. Two abstracts (one lay and one scientific) of his/her accomplishments over the term of the award.
3. A bibliography of all publications resulting from the research (submit pdf copies of publications).
4. A request for Open Access fee reimbursement, if applicable. (see VI-C)
5. A list of conferences and seminars attended and presentations given during the award year.
6. A brief description of collaborations and partnerships related to the Damon Runyon-funded research,with either academic and/or industry scientists. Please identify your collaborator(s) and his/heracademic/industrial affiliation(s).
7. A statement indicating how the Damon Runyon award made a difference to the Fellow.
8. A statement of future plans.
9. An up-to-date curriculum vitae.
10. A brief summary, from the Sponsor, assessing the Fellow’s scientific progress and professional
development.
11. A completed intellectual property disclosure form.
B.
Financial Expenditure Reports: The institution's financial officer must maintain a separate accountincluding receipts for each fellowship, and this account must be available for audit by representatives of theFoundation. Reports of expenditures on forms provided by the Foundation must be submitted within 60 days ofthe end of each award year. Any unexpended expense allowance may be carried over to the next award
year, but any unexpended stipend must be returned to the Foundation at the end of each fellowship year.
Upon termination or expiration of the fellowship, a final report of expenditures, with the refund of any
unexpended balance, must also be submitted within 60 days.
Financial Expenditure Report Preparation Guidelines:
1. Please use the form provided by the foundation (it is available on our website or can be requested
from alexi.studebaker@damonrunyon.org).
2. Indicate any carry-over of the previous year’s expense allowance in the second row as an amountreceived in addition to the current year’s $2,000 allowance.
3. If the expense allowance was used for travel, please provide the following details:
a. name and location of scientific meeting or conference attended
b. dates of meeting/conferencec. use of funds; restricted to registration fee, lodging, meals, transportation (if by train or plane,
must be coach class ticket only).
4. If the expense allowance was used for supplies, please provide a list of the general categories of the
supplies. If any one piece of equipment purchased costs $1,500 or more, please provide the name of
the item, date of purchase, and price.
5. The only allowable purchases that may be listed in the “other” category are:a. health insurance (if requested by the Fellow- see section I.E. above)b. scientific subscriptions
c. contact our office for approval of any items not listed here
6. The Foundation requires that the Dependent Child Allowance be reported as received in the annual
financial report, but does not require reporting on how the allowance is spent.
III. Confidentiality Agreements
Fellows may not enter into confidentiality agreements that prevent or delay them from publishing and/or
presenting their Damon Runyon-supported research.
IV. Relationship of Parties
Awards are made to the institutions to support the Fellow and the project set forth in his/her application. It is
understood by all parties that this award in no way constitutes an employer-employee relationship between theDamon Runyon Cancer Research Foundation and the recipient.
3

V. Intellectual Property Policy
All research grants, fellowships and other awards made by the Damon Runyon Cancer Research Foundation(“DRCRF”) are subject to this policy. By accepting an award from DRCRF for a research project, the grantee
and the institution(s) agree to be bound by the terms and conditions of this policy.
An essential part of DRCRF’s mission is to accelerate the translation of scientific breakthroughs into new
diagnostic tools and treatments for cancer, and DRCRF recognizes that discoveries having commercial
application or value may arise out of research supported by DRCRF. It is DRCRF’s intent that these
discoveries are widely disseminated and become available for the public benefit at the earliest possible time.
This policy sets forth DRCRF’s rights with respect to discoveries funded, in whole or in part, by DRCRF thathave commercial application or value.
For purposes of this policy, “Intellectual Property” is defined as any invention, data, material, method, product,
process, program, discovery, improvement, copyrightable work (excluding scientific publications) or otherwork product resulting from the performance of any research funded, in whole or in part, by DRCRF.
1.
Unless otherwise agreed, title to Intellectual Property will reside with the grantee institution pursuant to
the grantee institution’s intellectual property policies.
2.
The grantee institution will, at its own expense, use diligent efforts to obtain patent and/or copyrightprotection, as applicable, for the Intellectual Property and to grant licensees under such Intellectual Property to
third parties to commercialize the discoveries disclosed or claimed in the Intellectual Property in a thorough anddiligent manner.
3.
The grantee institution will inform DRCRF in writing promptly upon the filing of any patent application
constituting Intellectual Property and the execution of any license agreement under which rights to practice such
Intellectual Property commercially are granted to a third party. In addition, the grantee institution will provide
DRCRF, on an annual basis, a written report describing the status of all patent rights constituting Intellectual
Property, information regarding any licenses to commercialize the discoveries disclosed or claimed in theIntellectual Property, including consideration received under such licenses, and status of efforts by any licensees
to commercialize the discoveries.
4.
DRCRF will be entitled to receive a portion of all consideration, in any form, received by the grantee
institution that arise out of the licensing or other exploitation of Intellectual Property, after amounts are
distributed to individual inventors (but not distributions to institutional departments or laboratories) inaccordance with the grantee institution’s written policies. The portion of such consideration to which DRCRF
will be entitled will be equal to the quotient obtained by dividing (a) the amount of the award made by DRCRF
for the research that resulted in the Intellectual Property by (b) all direct costs provided by funding sources,
including DRCRF, for the research that resulted in the Intellectual Property, but in no event will Damon
Runyon’s portion exceed 50%. For clarity, costs associated with the recruiting of scientific staff, laboratory
start-up costs and other infrastructure costs may not be included in the foregoing calculation.
5.
The grantee institution will be entitled to credit the following against any amounts due to DRCRF under
this policy:(a)an amount equal to the product obtained by multiplying (a) the amount of the award made by
DRCRF for the research that resulted in the Intellectual Property and (b) the grantee institution’s approved NIH
indirect cost rate at the time the award was made; and4(b)the reasonable, out-of-pocket costs incurred by the grantee institution for the preparation, filingand prosecution of patent rights included in the Intellectual Property that have not been reimbursed by a third
party.
6.
DRCRF and the grantee institution will negotiate in good faith and execute a royalty-sharing agreement
consistent with the terms of this policy promptly following the filing of any patent application constitutingIntellectual Property, and before any rights are granted to a third party to commercialize the discoveries
disclosed or claimed in the Intellectual Property.
7.
All information of a confidential nature disclosed to DRCRF pursuant to this policy will be maintainedin confidence by DRCRF and will not be disclosed to any third party without the prior written consent of the
grantee institution.
VI. Publications/Website
A.
Publications/Website: Publications (including abstracts of presentations at scientific or clinicalmeetings) resulting from projects supported by the Foundation must carry the following acknowledgment:“[Name of Awardee] is a Damon Runyon Fellow supported by the Damon Runyon Cancer Research Foundation(DRG-[__]).” Awardees should identify themselves as Damon Runyon Fellows, particularly when presenting
their work at professional conferences, and on their websites.
B.
Public Access Policy: Damon Runyon Cancer Research Foundation (“Damon Runyon”) funds
biomedical research in order to better understand the causes of cancer and to advance its prevention, diagnosis
and treatment. The main output of this research is new knowledge. To ensure this knowledge can be accessed,
read, applied, and built upon in fulfillment of our goals, Damon Runyon expects its researchers to disseminate
their findings, including publishing in peer-reviewed journals.
In addition, it is a condition of Damon Runyon funding that all peer-reviewed articles supported in whole or inpart by its grants must be made available in the PubMed Central online archive. PubMed Central is a databaseof full-text biomedical journal articles available online without a fee, hosted by the National Library ofMedicine in the National Institutes of Health. Once posted in PubMed Central, results of research become moreaccessible, prominent, and integrated, making it easier for scientists worldwide to pursue biomedical research. It
also makes this information accessible to Damon Runyon and its donors, as well as patients, clinicians,
educators, students and others.
Damon Runyon award recipients are required to deposit an electronic copy of their final peer-reviewed
manuscripts in PubMed Central immediately upon acceptance for journal publication and take the steps
necessary to link that manuscript to the appropriate Damon Runyon grant. The manuscript is to be madepublicly available in PubMed Central no later than 12 months after the official date of journal publication. Thisrequirement applies to all Damon Runyon grants awarded after July 1, 2013.
Damon Runyon is part of the Health Research Alliance (HRA), a national consortium of non-governmental,
not-for-profit funders of biomedical research and training. HRA has made arrangements so that PubMed Central
will accept deposits of manuscripts and publications resulting from research funded by HRA member
organizations. All Damon Runyon award recipients are required to create an account with HRA through its
Public Access Initiative. Someone from our awards team will be contacting you with information on how tocreate your HRA account.
Damon Runyon award recipients must acknowledge Damon Runyon support in every article arising from suchfunding. The acknowledgement statement must include the applicable Damon Runyon grant number. This will
enable Damon Runyon to link the published outputs of research to the support it has provided.

5

Damon Runyon also encourages award recipients to publish in peer-reviewed open access journals with a policyof immediate availability of the published version without restriction, and permits use of non-salary/stipend
grant funds to pay associated publication fees.
C.
Open Access Fee Reimbursement Policy: Damon Runyon encourages and enables our scientists topublish in open access journals, which facilitates more rapid dissemination and broad use of their publications.
To do so, we have established an annual fund of $25,000 that is available on a first-come, first-served
basis to current awardees to pay fees incurred by publishing in open access journals.
• The publication must be based on Damon Runyon-funded research.
• Publications resulting from projects supported by the Foundation must carry the following
acknowledgment: “Name of Awardee is a Damon Runyon Fellow supported by the Damon Runyon
Cancer Research Foundation (DRG-___).”• Requests must be submitted during the Damon Runyon award period, or within 18 months of the award
end date.
• Scientists should submit a written request with 1) a copy of the invoice or receipt for publication feesfrom the journal, 2) PDF copy of the accepted publication, and 3) active URL link to the publication.
All requests will be reviewed. If approved and there is money remaining in the fund, the Foundation will
reimburse you for these fees.
VII. Publicity
Media coverage is to the advantage of both the host institution and the Damon Runyon Cancer Research
Foundation. In media releases resulting from projects supported by the Foundation, identify yourself as “Nameof Awardee, Damon Runyon Fellow.” Please notify the Foundation as soon as possible of all media releases.
The Foundation is willing and able to assist in any publicity related to the award.
VIII. Fellows’ Retreat
The Damon Runyon Cancer Research Foundation hosts an annual scientific retreat. First- and third-year
Fellows are required to attend. Fellows in their first year present a poster, while third-year Fellows present anoral presentation of their work. Travel expenses will be paid by the Foundation and need not come out of the$2,000 expense allowance.
IX. Termination
Upon premature termination of a fellowship, the Foundation must be notified immediately. A final report ofexpenditures (using the form provided) must be submitted within thirty days, along with the refund of any
unexpended balance. A final progress report must be submitted at this time including a completed intellectual
property form. (See II.A.)
X. Transfer
Transfers must be approved by the Fellowship Award Committee (FAC). If the Fellow is moving with his/herSponsor to another institution, letters from both the Sponsor and Fellow must be submitted to the Foundation
three months before the transfer takes place. If the Fellow is moving to a different Sponsor’s laboratory, theFellow is required to submit: a full description of the proposed project – 5 pages, single-spaced, 12-point type
(go to www.damonrunyon.org for details); an application cover sheet with appropriate signatures; a letter
explaining the reasons for the transfer; a letter from the proposed Sponsor with a copy of his/her curriculum
vitae and a reference from the Fellow’s original Sponsor or a senior member of the original institution who isfamiliar with the Fellow’s work. The transfer request will be reviewed by FAC. It will evaluate: 1) the
reason(s) for the transfer; 2) the training potential of the new environment; and 3) the new project, within the6overall scope of other Damon Runyon Fellowship supported research. To initiate the transfer process, pleasecall the Foundation.
XI. Parental Leave Policy
The Damon Runyon Foundation will allow up to 12 weeks of paid parental leave for birth/adoptive parents
consistent with their institution's policy. The Foundation must be notified in advance of the leave.
XII. Updating Information
The Foundation requests the most current information pertaining to change of address or position of the Fellow,
Sponsor, executive or fiscal officers of the institution in order to maintain an up-to-date database.
XIII. Visa Status
It is the responsibility of the host institution to make every effort to ensure that awardees comply with federal
immigration policy.
XIV. Modification to the Award
Should the Fellow and/or Sponsor wish to discontinue the project, leave the designated institution, take a leaveof absence for any reason or modify any agreement of the award letter, he or she must seek approval from theDamon Runyon Cancer Research Foundation in advance. Failure to comply with this requirement may
result in immediate termination of the award and may jeopardize any future awards to the institution
and/or Sponsor by the Foundation.

CMC 11/17
7